🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Hypofractionated Radiotherapy in Breast Cancer Patients With Prosthetic Reconstruction

RecruitingNAAges 18 Years - anyFemaleBarretos Cancer Hospital
NCT05491395 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

RATIONALE: Radiotherapy (RT) can be indicated to patients submitted to breast-conserving surgery, but, despite the benefits, adjuvant RT can cause contracture generated by tissue fibrosis in patients with immediate prosthetic reconstruction, which could cause prosthesis loss. The biological explanation of this outcome is not fully understood, but recent advances in the analysis of patient-derived blood can contribute to establishing a connection of molecular alterations related to this clinical outcome. There is not a consensus about using hypofractionated RT schemes for patients with BCS and breast reconstruction since no studies had investigated the reasons why some patients lose the prosthesis. PURPOSE: This study will evaluate G3 toxicity rate in breast cancer patients with immediate prosthetic reconstruction, submitted to hypofractionated radiotherapy, analyzing capsular contract

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Women with confirmed histological diagnosis of invasive ductal carcinoma and lobular breast carcinoma; * Radical mastectomy with immediate reconstruction with a prosthesis; * Patients indicated for adjuvant RT; * Any lymph node status; * With or without adjuvant chemotherapy; * ECOG performance status from 0-2; * \> 18 years old; * Informed Consent Form applied before any study-specific procedure. Exclusion Criteria: * Another histological diagnosis than invasive ductal carcinoma or lobular carcinoma; * Previous history of neoplasm and/or radiotherapy and/ or quimiotherapy before this study; * Distant metastatic disease; * Palliative treatment; * Patients with scleroderma / systemic lupus erythematosus.
💊

What it tests

  • Hypofractionation
📍

Where

1 site
Radiation Oncology Department
Barretos, Brazil
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy